Giovanni Mauri1,2, Duccio Rossi3,4, Samuele Frassoni5, Guido Bonomo1, Nicola Camisassi1, Paolo Della Vigna1, Vincenzo Bagnardi5, Daniele Maiettini1, Gianluca Maria Varano1, Maria Giulia Zampino6, Franco Orsi1. 1. Division of Interventional Radiology, IEO, European Institute of Oncology IRCCS, Milan, Italy. 2. Department of Oncology and Hematology-Oncology, University of Milan, 20122, Milan, Italy. 3. Division of Interventional Radiology, IEO, European Institute of Oncology IRCCS, Milan, Italy. duccio.rossi@unimi.it. 4. Postgraduate School of Radiodiagnostics, University of Milan, 20122, Milan, Italy. duccio.rossi@unimi.it. 5. Department of Statistics and Quantitative Methods, University of Milan-Bicocca, Milan, Italy. 6. Division of Gastrointestinal Medical Oncology and Neuroendocrine Tumors, IEO, European Institute of Oncology IRCCS, Milan, Italy.
Abstract
PURPOSE: The purpose of this study was to investigate survival outcomes and safety after chemoembolization using irinotecan-loaded small-size beads (DEB-IRI) in patients with colorectal liver metastases unresponsive to standard chemotherapy. MATERIALS AND METHODS: Between December 2013 and August 2019, fifty-five patients (32 males, median age 64.5 years) with pretreated colorectal liver metastases unresponsive to standard chemotherapy underwent 197 chemoembolization procedures (mean 3.6 ± 2.3 SD per patient). Thirty patients (30/55; 55%) had extrahepatic disease metastatic to the lungs, lymph nodes or peritoneum. Local tumor control was evaluated at 3, 6, 9 and 12 months. Median overall survival, survival rates at 1 and 2 year and adverse events were evaluated. RESULTS: Local tumor control was achieved in 32/55 (58%), 12/55 (22%), 4/55 (7%) and 2/55 (4%) patients at 3, 6, 9 and 12 months, respectively. Median overall survival was 9.9 months (95% CI: 6.2-14.2 months) with 1- and 2-year survival rates of 45% and 15%, respectively. A total of 30 (15%) G1-G3 treatment-related adverse events occurred across all embolization procedures. No severe treatment-related adverse events occurred. CONCLUSION: Chemoembolization using irinotecan-loaded small-size beads is a safe and effective procedure as a salvage treatment in patients with colorectal liver metastases, showing good results in terms of liver-specific progression free survival and overall survival.
PURPOSE: The purpose of this study was to investigate survival outcomes and safety after chemoembolization using irinotecan-loaded small-size beads (DEB-IRI) in patients with colorectal liver metastases unresponsive to standard chemotherapy. MATERIALS AND METHODS: Between December 2013 and August 2019, fifty-five patients (32 males, median age 64.5 years) with pretreated colorectal liver metastases unresponsive to standard chemotherapy underwent 197 chemoembolization procedures (mean 3.6 ± 2.3 SD per patient). Thirty patients (30/55; 55%) had extrahepatic disease metastatic to the lungs, lymph nodes or peritoneum. Local tumor control was evaluated at 3, 6, 9 and 12 months. Median overall survival, survival rates at 1 and 2 year and adverse events were evaluated. RESULTS: Local tumor control was achieved in 32/55 (58%), 12/55 (22%), 4/55 (7%) and 2/55 (4%) patients at 3, 6, 9 and 12 months, respectively. Median overall survival was 9.9 months (95% CI: 6.2-14.2 months) with 1- and 2-year survival rates of 45% and 15%, respectively. A total of 30 (15%) G1-G3 treatment-related adverse events occurred across all embolization procedures. No severe treatment-related adverse events occurred. CONCLUSION: Chemoembolization using irinotecan-loaded small-size beads is a safe and effective procedure as a salvage treatment in patients with colorectal liver metastases, showing good results in terms of liver-specific progression free survival and overall survival.
Authors: M J van Amerongen; E P van der Stok; J J Fütterer; S F M Jenniskens; A Moelker; D J Grünhagen; C Verhoef; J H W de Wilt Journal: Eur J Surg Oncol Date: 2016-01-23 Impact factor: 4.424
Authors: Giammaria Fiorentini; Camillo Aliberti; Massimo Tilli; Luca Mulazzani; Francesco Graziano; Paolo Giordani; Andrea Mambrini; Francesco Montagnani; Paolo Alessandroni; Vincenzo Catalano; Paolo Coschiera Journal: Anticancer Res Date: 2012-04 Impact factor: 2.480
Authors: Tatjana Gruber-Rouh; Nagy N N Naguib; Katrin Eichler; Hanns Ackermann; Stephan Zangos; Jörg Trojan; Martin Beeres; Marc Harth; Boris Schulz; Nour-Eldin Nour-Eldin A; Thomas J Vogl Journal: Int J Cancer Date: 2013-09-03 Impact factor: 7.396